Literature DB >> 15991799

Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer.

Johannes F Coy1, Dirk Dressler, Juergen Wilde, Peter Schubert.   

Abstract

Transketolase proteins or transketolase enzyme activities have been related to neurodegenerative diseases, diabetes, and cancer. Transketolase enzyme variants and reduced transketolase enzyme activities are present in patients with the neurodegenerative disease Wernicke-Korsakoff syndrome. In Alzheimer's disease patients transketolase protein variants with different isoelectric points or a proteolytic cleavage leading to small transketolase protein isoforms have been identified. In diabetes mellitus patients reduced transketolase enzyme activities have been detected and the lipid-soluble thiamine derivative benfotiamine activates transketolase enzyme reactions, thereby blocking three major pathways of hyperglycemic damage and preventing diabetic retinopathy. In cancer inhibition of transketolase enzyme reactions suppresses tumor growth and metastasis. All the observed phenomena have been interpreted solely on the basis of a single transketolase gene (TKT) encoding a single transketolase enzyme. No mutations have been identified so far in TKT transketolase explaining the altered transketolase proteins or transketolase enzyme activities found in neurodegenerative diseases, diabetes and cancer. We demonstrate the presence of a second transketolase enzyme (TKTL1) in humans. During the evolution of the vertebrate genome, mutations in this transketolase gene (TKTL1) have led to tissue-specific transcripts different in size, which encode an enzymatically active transketolase protein as well as different smaller protein isoforms. The mutations within the TKTL1 gene caused a mutant transketolase enzyme with an altered substrate specificity and reaction modus. Here we characterize the TKTL1 gene and its encoded TKTL1 protein(s) and discuss the medical and clinical implications of this mutated transketolase. We furthermore postulate a novel metabolic concept for the understanding, prevention and therapy of neurodegenerative diseases, diabetes and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991799

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  59 in total

Review 1.  The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review.

Authors:  M M C Wamelink; E A Struys; C Jakobs
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

2.  Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas.

Authors:  Martin Grimm; Wiebke Kraut; Sebastian Hoefert; Michael Krimmel; Thorsten Biegner; Peter Teriete; Marcel Cetindis; Joachim Polligkeit; Susanne Kluba; Adelheid Munz; Siegmar Reinert
Journal:  Clin Oral Investig       Date:  2015-07-08       Impact factor: 3.573

3.  Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.

Authors:  Eleonore Fröhlich; Inge Fink; Richard Wahl
Journal:  Invest New Drugs       Date:  2008-09-20       Impact factor: 3.850

4.  Targeting thiamine-dependent enzymes for metabolic therapies in oral squamous cell carcinoma?

Authors:  M Grimm; B Calgéer; P Teriete; T Biegner; A Munz; S Reinert
Journal:  Clin Transl Oncol       Date:  2015-07-16       Impact factor: 3.405

5.  TKTL1 expression and its downregulation is implicated in cell proliferation inhibition and cell cycle arrest in esophageal squamous cell carcinoma.

Authors:  Zuxuan Shi; Yu Tang; Ke Li; Qingxia Fan
Journal:  Tumour Biol       Date:  2015-06-02

6.  Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer.

Authors:  Kaisa Ahopelto; Camilla Böckelman; Jaana Hagström; Selja Koskensalo; Caj Haglund
Journal:  Cancer Biol Ther       Date:  2015-12-09       Impact factor: 4.742

7.  Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1.

Authors:  Gian Kayser; Ahmad Kassem; Wulf Sienel; Luzie Schulte-Uentrop; Dominik Mattern; Konrad Aumann; Elmar Stickeler; Martin Werner; Bernward Passlick; Axel zur Hausen
Journal:  Diagn Pathol       Date:  2010-04-12       Impact factor: 2.644

8.  Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.

Authors:  Christina Wanka; Joachim P Steinbach; Johannes Rieger
Journal:  J Biol Chem       Date:  2012-08-10       Impact factor: 5.157

9.  The role of glucose metabolism and glucose-associated signalling in cancer.

Authors:  Rainer Wittig; Johannes F Coy
Journal:  Perspect Medicin Chem       Date:  2008-01-18

10.  Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.

Authors:  Hans-Ullrich Völker; Matthias Scheich; Annette Berndt; Imme Haubitz; Alexandra Metzger; Hans-Konrad Müller-Hermelink; Ulrike Kämmerer; Melanie Schmidt
Journal:  Diagn Pathol       Date:  2009-06-19       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.